SM

SMS Pharmaceuticals LtdNSE SMSPHARMA Stock Report

Last reporting period 30 Sep, 2023

Updated 01 Nov, 2024

Last price

Market cap $B

0.047

Micro

Exchange

XNSE - National Stock Exchange Of India

SMSPHARMA.NS Stock Analysis

SM

Uncovered

SMS Pharmaceuticals Ltd is uncovered by Eyestock quantitative analysis.

Market cap $B

0.047

Dividend yield

0.11 %

Shares outstanding

84.652 B

SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 1,095 full-time employees. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The firm products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The firm has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.

View Section: Eyestock Rating